Skip to content
OpenCapital
Get started

Aardvark Therapeutics, Inc. Common Stock AARD Income Statement

Income StatementBalance SheetCash FlowRatiosSegments
QuarterlyAnnualTTM
YoY
SimplifiedDetailed
FY'25
Total interest income
$5.14M+113%
Total revenue
$0—
Research and development
$48.94M+182%
General and administrative
$13.79M+160%
Provision for credit losses
$0-100%
Other operating expenses
$62.73M+175%
Total operating expenses
$62.73M+175%
Operating income
-$62.73M-175%
Other income (expense), net
$5.13M+134%
Net income
-$57.59M-180%
Diluted earnings per share
-$2.93+43.1%
Basic earnings per share
-$2.93+43.1%
Weighted-average shares, diluted
76.2M+379%
Weighted-average shares, basic
76.2M+379%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
-$57.51M-179%
Interest and Dividend Income, Operating
$5.14M+113%
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
$82K—
EBIT
-$62.73M-175%
EBITDA
-$62.69M-175%
EBITDA
-$62.69M-175%
EBIT
-$62.73M-175%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Aardvark Therapeutics, Inc. Common Stock profitable?
Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.